Pharmaceutical company Pfizer has announced UK health tech firm Medopad as the 2018 winner of the Pfizer Healthcare Hub Competition, as part of the company’s Healthcare Hub start-up support scheme.
Pfizer’s competition is designed to help late stage start-ups grow by providing access to Pfizer’s global network and resources over the course of a year.
As the winner, Medopad plans to use the opportunity to accelerate growth in the UK and overseas markets by forging stronger relationships with those in Pfizer’s network and developing further commercial and clinical opportunities.
Medopad’s goal is to offer unique and personalised care to patients with complex and chronic diseases by transforming their connections with clinicians and healthcare providers remotely and in real time. The company has the ultimate aim of being able to use predictive analytics to prevent life threatening outcomes. It has seen 400% growth in the value of signed projects year-on-year since 2015.
When asked how the company came to win, Medopad brand marketing manager Kirsten Nehr told Verdict Medical Devices: “Over the past year, we have seen the business go from strength-to-strength both in terms of commercial reach as well as patient impact. We believe this has predominantly been due to our focus on developing solutions that simplify digital health for the patient, the provider and the pharmaceutical industry.
“Our belief is that Pfizer have chosen us for both being one of the most impactful businesses in the UK digital health community, whilst also having a focus on simplifying digital health through partnership and collaboration.”
Medopad’s Alex Gilbert added: “The Pfizer healthcare hub will be an excellent opportunity for us to partner with another organisation as motivated to transform patient care as Medopad are. Our vision to help people live longer is a big one and we know we will need partners to help us achieve this mission.
“We aim to leverage Pfizer’s experience and commitment to the UK healthcare system as well as our technological prowess to further develop the role of digital in the UK healthcare ecosystem. We are especially excited to explore the fields of oncology, rare diseases and neurodegenerative diseases under the guidance of a world-class therapy leader.”
Pfizer Healthcare Hub London manager Dr Hamish Graham said: “The broad array of innovative technology presented to us by the different start-ups at the pitch day was a real privilege to see. The judges were impressed by the ambition and focus of Medopad on transforming patients’ lives through innovative solutions to real health problems.
“We are looking forward to collaborating on some exciting projects in the next 12 months to help bring the potential of their technology to more patients in the UK”.
Medopad believes it can use the next 12 months to establish itself as one of the leading global digital health companies and hopes that support from Pfizer will further establish its NHS ties and allow the company to support patients in oncology, rare diseases and neurodegenerative diseases.